Cork, Ireland – Applied Biopharm Consulting Ltd has been awarded an Intellectual Property (IP) Start Grant from the Local Enterprise Office under Enterprise Ireland’s IP Strategy initiative.
The grant will support the company in securing specialist intellectual property advisory services to protect innovations emerging from its artificial intelligence-driven viral capsid engineering research program.
The IP Start Grant enables companies to engage external intellectual property specialists to conduct prior-art research and develop a formal patent strategy. Applied Biopharm Consulting will use this support to evaluate and protect biomolecular innovations arising from its proprietary computational platform for engineered viral vector design.
Building on a 2024 feasibility study supported by the Local Enterprise Office Cork North & West, the company has continued developing advanced methods that integrate artificial intelligence, structural bioinformatics and molecular simulation techniques to improve the performance of engineered adeno-associated virus (AAV) vectors.
The platform is designed to enhance vector targeting and binding interactions with potential applications across a range of advanced therapeutic modalities, including next-generation gene therapies and precision biologics development.
Initial research outcomes indicate strong potential for protectable innovations across key aspects of viral vector engineering and computational biomolecular design, supporting the company’s long-term strategy to develop proprietary technologies alongside its established consulting services.
Dr. Anthony Newcombe, Managing Director of Applied Biopharm Consulting Ltd, said:
“Securing the IP Start Grant represents an important milestone as we transition our capsid engineering research from early feasibility toward protected innovation. As we continue advancing AI-driven molecular design capabilities for viral vector development, establishing a strong intellectual property foundation is essential to maximising long-term value and enabling future partnerships.”
A spokesperson for the Local Enterprise Office Cork North & West added:
“We are pleased to support Applied Biopharm Consulting through the IP Start Grant under Enterprise Ireland’s IP Strategy initiative. Protecting intellectual property is a crucial step for innovative companies as they scale and commercialise their technologies, and we look forward to seeing the continued progression of this advanced research programme.”
The grant underscores Applied Biopharm Consulting’s strategic expansion beyond consulting services into proprietary biotechnology innovation, while maintaining its core focus on supporting global biopharmaceutical companies in GMP compliance, Regulatory CMC, Manufacturing Science and Technology (MSAT), Quality Assurance and technology transfer activities.
By combining extensive regulatory and manufacturing expertise with next-generation biologics engineering capabilities, the company is positioning itself at the intersection of advanced therapy development, viral vector and AI-driven biomolecular engineering.
About Applied Biopharm Consulting Ltd
Applied Biopharm Consulting Ltd is a specialist bioprocess and GMP consulting firm supporting biopharmaceutical and advanced therapy companies worldwide. The company provides expertise in Regulatory CMC, GMP auditing and compliance, Manufacturing Science and Technology (MSAT), technology transfer, GMP manufacturing and Quality Assurance.
In parallel with its consulting activities, Applied Biopharm Consulting is advancing an internal research and development programme focused on next-generation viral vector engineering and AI-driven molecular design. This initiative leverages the company’s regulatory, manufacturing and process development expertise to support the development of innovative technologies for the development of next-generation viral vector technologies.
For more information, please contact:
Anthony Newcombe, Managing Director
Applied Biopharm Consulting Ltd
Mob: +353 (0) 873634486
Sharleen Foody, Senior Enterprise Development Officer
Mob: +353 (22) 43235
